The effect of androgen-replacement therapy on prostate growth: A systematic review and meta-analysis

European Urology

Volumn 64, Issue 5, 2013, Pages 811-822

  Cui, Yuanshan ^a   Zhang, Yong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Androgens; Meta analysis; Prostate; Randomized controlled trial

Indexed keywords

ANDROSTANOLONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN THERAPY; HUMAN; HYPOGONADISM; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; META ANALYSIS; ORGAN GROWTH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE GROWTH; PROSTATE VOLUME; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; URINE FLOW RATE;

ANDROGENS; META-ANALYSIS; PROSTATE; RANDOMIZED CONTROLLED TRIAL;

ANDROGENS; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; ORGAN SIZE; PROSTATE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885423616     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.042     Document Type: Review

References (38)

1. A.B. Araujo, G.R. Esche, and V. Kupelian Prevalence of symptomatic androgen deficiency in men J Clin Endocrinol Metab 92 2007 4241 4247
2. S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, and M.R. Blackman Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging J Clin Endocrinol Metab 86 2001 724 731
3. F.C. Wu, A. Tajar, and S.R. Pye Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors J Clin Endocrinol Metab 93 2008 2737 2745
4. C. Wang, E. Nieschlag, and R. Swerdloff Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations Eur Urol 55 2009 121 130
5. A. Morales, C.C. Schulman, J. Tostain, and F.C.W. Wu Testosterone deficiency syndrome (TDS) needs to be named appropriately - the importance of accurate terminology Eur Urol 50 2006 407 409
6. J.M. Kaufman, and A. Vermeulen The decline of androgen levels in elderly men and its clinical and therapeutic implications Endocr Rev 26 2005 833 876
7. J.B. Meigs, B. Mohr, M.J. Barry, M.M. Collins, and J.B. McKinlay Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men J Clin Epidemiol 54 2001 935 944
8. C.G. Roehrborn, P. Boyle, J.C. Nickel, K. Hoefner, and G. Andriole Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441
9. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study Eur Urol 57 2010 123 131
10. J.E. Fowler Jr., and W.F. Whitmore Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer Cancer 49 1982 1373 1377
11. J.D. McConnell Prostatic growth: new insights into hormonal regulation Br J Urol 76 Suppl 1 1995 5 10
12. A.R. Jadad Randomised controlled trials 1998 BMJ Publishing Group London, UK
13. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, v.5.1. Cochrane Collaboration Web site. http://www.cochrane- handbook.org/. Updated March 2011.
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
15. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
16. J.S. Tenover Effects of testosterone supplementation in the aging male J Clin Endocrinol Metab 75 1992 1092 1098
17. R. Sih, J.E. Morlet, F.E. Kaiser, H.M. Perry III, P. Patrick, and C. Ross Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial J Clin Endocrinol Metab 82 1997 1661 1667
18. P.J. Snyder, H. Peachey, and P. Hannoush Effect of testosterone treatment on bone mineral density in men over 65 years of age J Clin Endocrinol Metab 84 1999 1966 1972
19. A.M. Kenny, K.M. Prestwood, C.A. Gruman, K.M. Marcello, and L.G. Raisz Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels J Gerontol A Biol Sci Med Sci 565 2001 266 272
20. G.A. Wittert, I.M. Chapman, M.T. Haren, Mackintosh, P. Coates, and J.E. Morley Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status J Gerontol A Biol Sci Med Sci 587 2003 618 625
21. J.K. Amory, N.B. Watts, and K.A. Easley Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone J Clin Endocrinol Metab 89 2004 503 510
22. A.M. Kenny, G. Fabregas, C. Song, B. Biskup, and S. Bellantonio Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss J Gerontol A Biol Sci Med Sci 591 2004 75 78
23. L.S. Marks, N.A. Mazer, and E. Mostaghel Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism JAMA 296 2006 2351 2361
24. H.S. Chiang, T.I.S. Hwang, and Y.S. Hsui Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function Int J Impot Res 19 2007 411 417
25. M.H. Emmelot-Vonk, H.J.J. Verhaar, and H.R.N. Pour Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men JAMA 299 2008 39 52
26. U. Srinivas-Shankar, S.A. Roberts, and M.J. Connolly Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study J Clin Endocrinol Metab 95 2010 639 650
27. A. Aversa, R. Bruzziches, and D. Francomano Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study J Sex Med 7 2010 3495 3503
28. A. Idan, K.A. Griffiths, and D.T. Harwood Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease Ann Intern Med 153 2010 621 632
29. K. Shigehara, K. Sugimoto, and H. Konaka Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study Aging Male 14 2011 53 58
30. S.T. Page, D.W. Lin, and E.A. Mostaghel Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial J Clin Endocrinol Metab 96 2011 430 437
31. S. Holmang, P. Marin, G. Lindstedt, and H. Hedelin Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men Prostate 23 1993 99 106
32. C. Wang, N. Berman, and J.A. Longstreth Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study J Clin Endocrinol Metab 85 2000 964 969
33. R.S. Swerdloff, C. Wang, and G. Cunningham Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men J Clin Endocrinol Metab 85 2000 4500 4510
34. S. Bhasin, T.G. Travison, and T.W. Storer Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial JAMA 307 2012 931 939
35. A.S. Polackwich, K.A. Ostrowski, and J.C. Hedges Testosterone replacement therapy and prostate health Curr Urol Rep 13 2012 441 446
36. A. Morgentaler, and A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 2009 310 321
37. M.J. Diver, K.E. Imtiaz, A.M. Ahmad, J.P. Vora, and W.D. Fraser Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men Clin Endocrinol 58 2003 710 717
38. W. Rosner, R.J. Auchus, R. Azziz, P.M. Sluss, and H. Raff Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement J Clin Endocrinol Metab 92 2007 405 413